BDBM50102671 CHEMBL3343047

SMILES COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccc3)cc2)c(N)cc1O

InChI Key InChIKey=CKGRPOQFYXSXGV-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 50102671   

TargetAurora kinase B(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50102671(CHEMBL3343047)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human AURKB incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50102671(CHEMBL3343047)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human IRAK4 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50102671(CHEMBL3343047)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human JAK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50102671(CHEMBL3343047)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human JAK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50102671(CHEMBL3343047)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human JAK3 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 1(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50102671(CHEMBL3343047)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 2(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50102671(CHEMBL3343047)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetBifunctional protein GlmU(Escherichia coli (strain K12))
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50102671(CHEMBL3343047)
Affinity DataIC50: 5.90E+3nMAssay Description:Inhibition of Escherichia coli ATCC 27325 GlmU expressed in Escherichia coli HMS174(DE3) incubated for 15 mins prior to MgCl2 addition measured after...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-dependent kinase 9(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50102671(CHEMBL3343047)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetInterleukin-1 receptor-associated kinase 1(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50102671(CHEMBL3343047)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human IRAK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed